158 related articles for article (PubMed ID: 15869404)
21. Emerging combination therapies to overcome resistance in EGFR-driven tumors.
Ratti M; Tomasello G
Anticancer Drugs; 2014 Feb; 25(2):127-39. PubMed ID: 24113593
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of HER-2 inhibitors.
Rabindran SK
Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
[TBL] [Abstract][Full Text] [Related]
23. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
25. ErbB-targeted therapeutic approaches in human cancer.
Arteaga CL
Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro.
Gray ME; Lee S; McDowell AL; Erskine M; Loh QTM; Grice O; Argyle DJ; Bergkvist GT
Vet Comp Oncol; 2017 Sep; 15(3):890-909. PubMed ID: 27229930
[TBL] [Abstract][Full Text] [Related]
28. EGFR signaling and drug discovery.
Lurje G; Lenz HJ
Oncology; 2009; 77(6):400-10. PubMed ID: 20130423
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
30. Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
Menendez JA; Lupu R
J Clin Oncol; 2007 Jun; 25(17):2496-8; author reply 2499. PubMed ID: 17557968
[No Abstract] [Full Text] [Related]
31. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
32. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
34. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms.
Kirschbaum MH; Yarden Y
J Cell Biochem Suppl; 2000; 34():52-60. PubMed ID: 10762015
[TBL] [Abstract][Full Text] [Related]
35. Targeting the HER-kinase axis in cancer.
Gross ME; Shazer RL; Agus DB
Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
[TBL] [Abstract][Full Text] [Related]
36. The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics.
Sun GC; Yang X; Yu Y; Zhao DW
Anticancer Agents Med Chem; 2015; 15(7):869-80. PubMed ID: 25783965
[TBL] [Abstract][Full Text] [Related]
37. ERBB receptors and cancer: the complexity of targeted inhibitors.
Hynes NE; Lane HA
Nat Rev Cancer; 2005 May; 5(5):341-54. PubMed ID: 15864276
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics.
Hervent AS; De Keulenaer GW
Int J Mol Sci; 2012 Sep; 13(10):12268-86. PubMed ID: 23202898
[TBL] [Abstract][Full Text] [Related]
39. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development.
Kamath S; Buolamwini JK
Med Res Rev; 2006 Sep; 26(5):569-94. PubMed ID: 16788977
[TBL] [Abstract][Full Text] [Related]
40. [Molecular tumour therapy: antibodies and small molecules].
Wilhelm C; Neubauer A
Internist (Berl); 2008 May; 49(5):581-92. PubMed ID: 18373074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
